22
total announcements
BALAXI.NS · 15 min delayed
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has received WHO-GMP Certification for its first pharmaceutical formulation manufacturing facility, a significant milestone in the company's journey towards establishing its own manufacturing capabilities.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has informed the Exchange regarding the re-appointment of Ms. Akshita Ostwal as an Independent Director of the Company for a second term of five consecutive years.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has submitted the Exchange a copy of the Srutinizers Report of the Annual General Meeting held on 24th August, 2026, and informed the Exchange regarding Voting Results.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026, through video conferencing. The meeting was attended by the Chairman, Managing Director, Independent Directors, Key Managerial Personnel, Statutory Auditors, and Secretarial Auditors. The meeting discussed various resolutions, including the Statutory Auditors' Reports and the Secretarial Audit Report, and voted on several items through remote e-voting and e-voting at the meeting.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals has informed the Exchange about a Special Window for Transfer and Dematerialisation of Physical Securities, allowing shareholders to lodge or re-lodge transfer and dematerialisation requests for physical shares sold or purchased prior to April 1, 2019.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has informed the Exchange about a copy of newspaper publication regarding the Corrigendum to the Notice of the 83rd Annual General Meeting of the Company.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has issued a corrigendum to the notice of the 83rd Annual General Meeting (AGM) due to a typographical error in the cut-off date for determining the eligibility of members to cast their vote through remote e-Voting and voting during the AGM. The corrected cut-off date is 17th August, 2026.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has informed the Exchange regarding the RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended July 2026, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated 30th January, 2026.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has informed the Exchange about Investor Presentation, highlighting the Financial Results for the quarter ended 30th June, 2026. The presentation showcases the company's growth in frontier markets, expansion plans, and its first pharmaceutical formulation manufacturing unit.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has published unaudited financial results for the quarter ended June 30, 2026, showing a net profit of Rs. 163.89 crores and earnings per share of Rs. 3.24.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has informed the Exchange regarding the progress of its first pharmaceutical formulation plant at Jadcherla, Hyderabad. The Board of Directors noted that the Company has successfully commenced commercial production at the facility with its initial two products, Paracetamol Tablets 500mg and Piroxicam Capsules 20mg. The Company has received manufacturing product permissions for an additional 29 products, taking the total approved commercial product portfolio to 31 products.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has announced its standalone and consolidated unaudited financial results for the quarter ended 30th June, 2026. The company has reported a net loss of Rs. 125.32 lakhs, with a basic EPS of Rs. (0.23) and a diluted EPS of Rs. (0.23). The company has also commenced commercial production at its first pharmaceutical formulation manufacturing facility at Jadcherla, Hyderabad, and has received manufacturing product permissions for an additional 29 products.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has submitted its financial results for the quarter ended 30th June, 2026.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication post-dispatch of the 83rd AGM Notice and Annual Report (FY 2025-26) to the shareholders of the Company.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, which is part of its Annual Report for the same period.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has informed the Exchange regarding Notice of 83rd Annual General Meeting to be held on 24th August, 2026. The meeting will be held through Video Conferencing / Other Audio Visual Means (VC/OAVM) and will consider and adopt the Audited Standalone Financial Statements for the financial year ended March 31, 2026, and the reports of the Board of Directors and Auditors thereon. The meeting will also consider the re-appointment of Mrs. Minoshi Maheshwari as an Independent Director of the Company.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication regarding the 83rd Annual General Meeting to be held on 24th August, 2026, through Video Conferencing/OAVM and e-voting.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has clarified discrepancies in its financial results for the quarter ended March 31, 2026, correcting errors in employee benefit expense and other comprehensive income in the standalone and consolidated XBRL filings.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals has informed the Exchange regarding the re-lodgement of transfer requests of physical shares for the period ended June 2026, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated 30th January, 2026.
BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance with dematerialization of securities for the quarter ended 30th June, 2026.